Compare PSQH & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | SNTI |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 53.6M |
| IPO Year | N/A | N/A |
| Metric | PSQH | SNTI |
|---|---|---|
| Price | $1.07 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 613.1K | 353.3K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,534,522.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.49 | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 196.08 | N/A |
| 52 Week Low | $0.92 | $1.03 |
| 52 Week High | $4.99 | $5.10 |
| Indicator | PSQH | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 35.19 |
| Support Level | $1.00 | $1.04 |
| Resistance Level | $1.34 | $1.16 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 17.88 | 0.00 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.